FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 02/25/2020 |
3. Issuer Name and Ticker or Trading Symbol
GenMark Diagnostics, Inc. [ GNMK ] |
|||||||||||||
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 178,516(1) | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (Right to Buy) | (2) | 03/06/2023 | Common Stock | 1,500 | $10.89 | D | |
Stock Option (Right to Buy) | (2) | 03/06/2024 | Common Stock | 5,200 | $12.3 | D | |
Stock Option (Right to Buy) | (2) | 02/19/2025 | Common Stock | 8,500 | $13.17 | D | |
Stock Option (Right to Buy) | (2) | 10/21/2025 | Common Stock | 10,000 | $7.9 | D | |
Market Stock Units | (3) | (3) | Common Stock | 25,000 | $0.0 | D |
Explanation of Responses: |
1. The amount reported reflects common stock held by the Reporting Person as well as restricted stock units granted to a Reporting Person Pursuant to the Issuer's 2010 Equity Incentive Plan. Of the aggregate amount reported, 100,375 shares represent restricted stock units that vest 25% on the first anniversary of the grant date and the remaining shares subject to each award vest in 12 equal quarterly installments thereafter. In addition, 37,500 shares represent restricted stock units that vest 50% on the first anniversary of the grant date and the remaining shares subject to such award vest in 4 equal quarterly installments thereafter. |
2. The stock option is fully vested. |
3. The MSUs vest in three equal installments, on each of December 31, 2020, December 31, 2021, and December 31, 2022; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. |
Remarks: |
/s/ Eric Stier, Attorney-in-fact | 03/05/2020 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |